Q-omics provides the consensus-scored ZNF804A profile across patient tissues and cancer cell-line models. ZNF804A expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZNF804A is differentially expressed in 12, with the highest sampling consensus in KIRP. Additionally, ZNF804A RNA expression shows 14,949 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, KIRP, and THYM as cancer lineages where ZNF804A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF804A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF804A survival associations across molecular data types. ZNF804A RNA expression shows survival associations in the most cancer types (18), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF804A RNA expression–survival associations across cancer types. High ZNF804A expression shows unfavorable associations in MESO, UVM, SCLC and LUSC, but favorable associations in HNSC and LGG. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ZNF804A RNA expression.
This table summarizes ZNF804A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF804A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF804A shows lower tumor expression in KIRP, COAD, LUAD and THCA and higher tumor expression in BRCA and HNSC. The KIRP box plot shows higher ZNF804A RNA expression in normal versus tumor tissue (log2 FC = −0.861, t-test p < 0.001).
This table shows molecular features associated with ZNF804A in patient tissues and cancer cell lines. In patient samples, ZNF804A shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF804A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
